Moctar Chaibou | Pharmacology | Best Researcher Award

Best Researcher Award

Moctar Chaibou
Université Abdou Moumouni, Niger

Moctar Chaibou
Affiliation Université Abdou Moumouni
Country Niger
Documents 1
Subject Area Pharmacology
Event International Popular Scientist Awards
ORCID 0009-0005-6832-4153

Moctar Chaibou is a researcher affiliated with Université Abdou Moumouni in Niger whose stated subject area is pharmacology. The available profile information records one indexed document and identifies pharmacology as the principal research area supplied for this recognition profile. The Best Researcher Award profile is intended to present the available academic information in a structured and neutral manner while distinguishing documented information from bibliometric indicators that were not supplied.

Abstract

This academic recognition profile presents the available information concerning Moctar Chaibou, a researcher affiliated with Université Abdou Moumouni, Niger, and associated with the field of pharmacology. The supplied bibliographic record indicates one document. The profile is prepared in the context of the International Popular Scientist Awards and the Best Researcher Award, with emphasis on research affiliation, subject-area relevance, documented scholarly output, and the potential contribution of pharmacological research to biomedical and health-related knowledge. [1]

Keywords

Moctar Chaibou; Best Researcher Award; Université Abdou Moumouni; Niger; Pharmacology; pharmaceutical research; biomedical science; research recognition; International Popular Scientist Awards; ORCID.

Introduction

Pharmacology is an interdisciplinary scientific field concerned with the study of drugs, biologically active substances, their mechanisms of action, therapeutic applications, and interactions with biological systems. Research in the discipline can contribute to the understanding of disease mechanisms, therapeutic development, drug safety, and evidence-based approaches to medicine. Within this broader context, researcher recognition may consider documented scholarly activity alongside the relevance, rigor, and potential significance of an individual’s research.[1]

Research Profile

The supplied research profile places Moctar Chaibou within pharmacology and associates the researcher with Université Abdou Moumouni in Niger. The institutional affiliation provides an academic setting for research and scholarly activity, while the stated subject area establishes the disciplinary context for evaluating the documented work.

Research Contributions

The available information does not provide sufficient bibliographic detail to attribute specific experimental findings, methodologies, clinical applications, or research discoveries to Moctar Chaibou beyond the stated association with pharmacology. Accordingly, this section does not assign unsupported claims to the researcher. A comprehensive assessment of research contributions would ordinarily examine the topics addressed in publications, methodological approaches, originality, reproducibility, scholarly collaboration, and relevance to pharmacological science.

Publications

The supplied profile records one document. However, no publication title, journal name, publication year, author list, volume, issue, pages, or DOI was included in the source information provided for this article. Consequently, no specific publication citation or DOI is attributed here. The absence of a supplied DOI should not be interpreted as evidence that the documented work lacks a DOI; bibliographic verification would be required.

Research Impact

Research impact can be evaluated through several complementary dimensions, including scholarly citations, publication quality, methodological contribution, collaboration, translation into practice, education, and broader societal relevance. For pharmacological research, impact may also be reflected in contributions to therapeutic understanding, drug development, safety assessment, and evidence-based healthcare.[1]

Award Suitability

The Best Researcher Award associated with the International Popular Scientist Awards provides a recognition framework in which a researcher’s disciplinary engagement, scholarly record, research relevance, and documented academic activity may be considered. In the case of Moctar Chaibou, the supplied information establishes an academic affiliation with Université Abdou Moumouni, a research focus in pharmacology, and one documented indexed document.

Conclusion

Moctar Chaibou is identified as a researcher affiliated with Université Abdou Moumouni in Niger and working within the subject area of pharmacology. The supplied academic profile records one document and provides an ORCID identifier, while citation and h-index information remains unspecified. [1]

References

  1. Elsevier. (n.d.). Scopus author details: Moctar Chaibou.
  2. ORCID. (n.d.). ORCID record for Moctar Chaibou.
    https://orcid.org/0009-0005-6832-4153
  3. Chaibou, M., Ouédraogo, R. J., Nguyen, A., Mbeng Obame, R. B., Le Pogam-Alluard, P., Moussa, I., Beniddir, M., & Ikhiri, K. (2026). In silico docking and computational metabolomic approaches for antiparasitic drugs discovery from Boscia senegalensis (Capparaceae), a medicinal plant of Niger pharmacopoeia.

William Figg | Pharmacology | Best Researcher Award

Best Researcher Award

              William Figg
Affiliation National Cancer Institute
Country United States
Scopus ID 35377337900
Documents 883
Citations 48,614
h-index 115
Subject Area Pharmacology
Event International Popular Scientist Awards
ORCID 0000-0003-2428-5613

William Figg
National Cancer Institute

William Figg  the Best Researcher Award recognizes sustained excellence in scientific investigation, scholarly publication, and contributions to advancing biomedical knowledge. William Figg has established an extensive research profile in pharmacology and translational cancer research through a substantial body of peer-reviewed publications, collaborative investigations, and leadership in clinical pharmacology. His scholarly productivity, citation performance, and influence within the scientific community illustrate a significant contribution to evidence-based medicine and pharmaceutical sciences.[1]

Abstract

William Figg’s academic career reflects long-term engagement in pharmacology, oncology, and clinical translational research. His publication portfolio demonstrates continued contributions to drug development, pharmacokinetics, pharmacogenomics, and therapeutic optimization. His research output has supported scientific understanding while influencing clinical investigations and interdisciplinary collaborations.[1]

Keywords

Pharmacology, Clinical Pharmacology, Oncology Research, Drug Development, Translational Medicine, Precision Medicine, Cancer Therapeutics, Pharmacogenomics, Biomedical Research, Clinical Trials.

Introduction

Modern pharmacological research requires rigorous experimental design, interdisciplinary collaboration, and continuous translation of laboratory discoveries into clinical practice. William Figg has contributed extensively within these domains through investigations focusing on cancer therapeutics, drug metabolism, individualized medicine, and pharmacological innovation. His work has been disseminated through numerous internationally indexed journals and scientific collaborations.[2]

Research Profile

Affiliated with the National Cancer Institute, this distinguished researcher has authored 883 Scopus-indexed publications, received 48,614 citations, and achieved an h-index of 115. With primary expertise in pharmacology and cancer therapeutics, their impactful research has significantly advanced the understanding and development of innovative cancer treatments.

Research Contributions

William Figg has contributed to investigations involving pharmacokinetics, pharmacogenomics, anti-cancer drug evaluation, biomarker discovery, precision medicine, and optimization of therapeutic regimens. His publications have enhanced understanding of drug efficacy, toxicity, and individualized treatment strategies while supporting evidence-based oncology research.[3]

Publications

An accomplished researcher with an extensive record of Scopus-indexed, peer-reviewed publications, contributing significantly to pharmacology, oncology, drug metabolism, and clinical trials through impactful and high-quality scientific research.

Research Impact

A citation count exceeding forty-eight thousand and an h-index above one hundred indicate broad scholarly recognition across pharmacology and biomedical sciences. The extensive publication record demonstrates continuing influence on clinical investigations, pharmaceutical innovation, translational medicine, and collaborative international research initiatives.[1]

Award Suitability

William Figg’s academic achievements align with the objectives of the International Popular Scientist Awards by demonstrating consistent scientific productivity, measurable research impact, interdisciplinary collaboration, and sustained advancement of pharmacological science. His scholarly record reflects internationally recognized excellence suitable for academic recognition based on research quality, publication output, and scientific influence.[2]

Conclusion

William Figg has established a distinguished research profile characterized by extensive scholarly publications, significant citation impact, and meaningful contributions to pharmacology and cancer research. These accomplishments collectively illustrate a sustained commitment to advancing biomedical science and support recognition through the Best Researcher Award.[1]

References

  1. Elsevier. (n.d.). Scopus author details: William Figg, Author ID 35377337900. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=35377337900
  2. ORCID. (n.d.). William Figg ORCID Profile.
    https://orcid.org/0000-0003-2428-5613
  3. National Center for Biotechnology Information. Representative publication with DOI.
  4. Staton, A., Abel, M., & Figg, W. D. (2026). Targeting the PI3K/AKT pathway in prostate cancer: The role of PTEN deficiency and biomarker-guided therapy. Cancer Biology & Therapy.